


[Fig. 1]





[Fig. 2]





[Fig. 3]




[Fig. 4]


KCNJ1
Fold change
10
8
6
4
2
0
**
**
Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole


[Fig. 5]


TNF-α
Fold change
20
15
10
5
0
***
***
*
Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole
II6
Fold change
15
10
5
0
***
***
Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole
II1b
Fold change
100
80
60
40
20
0
*
*
Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole
Muc2
Fold change
2.0
1.5
1.0
0.5
0.0
**
**
*
Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole


[Fig. 6]


Control
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole
Goblet cell loss
score
***
*
Veh
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole


[Fig. 7]


Histological score
score
***
**
*
Veh
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole


[Fig. 8]


FITC-dextran flux
Permeability (% of control)
800
600
400
200
0
*
*
**
Veh
DSS+Veh
DSS+Tegoprazan
DSS+Rabeprazole


[Fig. 9]


Body weight change (%)
140
120
100
80
60
0
1
2
3
4
5
Day
***
###
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole


[Fig. 10]


12
11
10
9
8
7
6
Colon length (cm)
*
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole


[Fig. 11]



8
6
4
2
0
DAI score
0
1
2
3
4
5
Day
***
###
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole

[Fig. 12]



Il17
Fold change
3
2
1
0
***
***
**
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole

[Fig. 13]



Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole


Goblet cell loss score
0
1
2
3
4
5
*
***
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole

[Fig. 14]


Histological score
10
8
6
4
2
0
***
*
**
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole

[Fig. 15]


% survival
150
100
50
0
0
1
2
3
4
5
Day
Control
DNBS+Vehicle
DNBS+Tegoprazan
DNBS+Rabeprazole